Transfusions are used for various medical conditions to replace lost components of the blood.
White blood cells are not commonly used during transfusion, but are part of the immune system, and fight infections.
Plasma is the "yellowish" liquid part of blood, which acts as a buffer, and contains proteins and important substances needed for the body's overall health.
Platelets are involved in blood clotting, preventing the body from bleeding.
Before these components were known, doctors believed that blood was homogenous.
Because of this, many patients died because incompatible blood was transferred to them.
Red cell transfusion
Main article: Packed red blood cells
Because each unit of blood given carries risks, a trigger level lower than that, at 7 to 8 g/dL, is now usually used, as it has been shown to have better patient outcomes.
The administration of a single unit of blood is the standard for hospitalized people who are not bleeding, with this treatment followed with re-assessment and consideration of symptoms and hemoglobin concentration.
Patients with poor oxygen saturation may need more blood.
The advisory caution to use blood transfusion only with more severe anemia is in part due to evidence that outcomes are worsened if larger amounts are given.
One may consider transfusion for people with symptoms of cardiovascular disease such as chest pain or shortness of breath.
In cases where patients have low levels of hemoglobin due to iron deficiency, but are cardiovascularly stable, parenteral iron is a preferred option based on both efficacy and safety.
Other blood products are given where appropriate, e.g., to treat clotting deficiencies.
Before a blood transfusion is given, there are many steps taken to ensure quality of the blood products, compatibility, and safety to the recipient.
In 2012, a national blood policy was in place in 70% of countries and 69% of countries had specific legislation that covers the safety and quality of blood transfusion.
Main article: Blood donation
The latter is much more common than the former.
Using another's blood must first start with donation of blood.
In developed countries, donations are usually anonymous to the recipient, but products in a blood bank are always individually traceable through the whole cycle of donation, testing, separation into components, storage, and administration to the recipient.
This enables management and investigation of any suspected transfusion related disease transmission or transfusion reaction.
In developing countries, the donor is sometimes specifically recruited by or for the recipient, typically a family member, and the donation occurs immediately before the transfusion.
It is unclear whether applying alcohol swab alone or alcohol swab followed by antiseptic is able to reduce contamination of donor's blood.
Processing and testing
Donated blood is usually subjected to processing after it is collected, to make it suitable for use in specific patient populations.
Collected blood is then separated into blood components by centrifugation: red blood cells, plasma, platelets, albumin protein, clotting factor concentrates, cryoprecipitate, fibrinogen concentrate, and immunoglobulins (antibodies).
Red cells, plasma and platelets can also be donated individually via a more complex process called apheresis.
- The World Health Organization (WHO) recommends that all donated blood be tested for transfusion transmissible infections. These include HIV, Hepatitis B, Hepatitis C, Treponema pallidum (syphilis) and, where relevant, other infections that pose a risk to the safety of the blood supply, such as Trypanosoma cruzi (Chagas disease) and Plasmodium species (malaria). According to the WHO, 25 countries are not able to screen all donated blood for one or more of: HIV; Hepatitis B; Hepatitis C; or syphilis. One of the main reasons for this is because testing kits are not always available. However the prevalence of transfusion-transmitted infections is much higher in low income countries compared to middle and high income countries.
- All donated blood should also be tested for the ABO blood group system and Rh blood group system to ensure that the patient is receiving compatible blood.
- In addition, in some countries platelet products are also tested for bacterial infections due to its higher inclination for contamination due to storage at room temperature. Presence of cytomegalovirus (CMV) may also be tested because of the risk to certain immunocompromised recipients if given, such as those with organ transplant or HIV. However, not all blood is tested for CMV because only a certain amount of CMV-negative blood needs to be available to supply patient needs. Other than positivity for CMV, any products tested positive for infections are not used.
- Leukocyte reduction is the removal of white blood cells by filtration. Leukoreduced blood products are less likely to cause HLA alloimmunization (development of antibodies against specific blood types), febrile non-hemolytic transfusion reaction, cytomegalovirus infection, and platelet-transfusion refractoriness.
- Pathogen Reduction treatment that involves, for example, the addition of riboflavin with subsequent exposure to UV light has been shown to be effective in inactivating pathogens (viruses, bacteria, parasites and white blood cells) in blood products. By inactivating white blood cells in donated blood products, riboflavin and UV light treatment can also replace gamma-irradiation as a method to prevent graft-versus-host disease (TA-GvHD).
Before a recipient receives a transfusion, compatibility testing between donor and recipient blood must be done.
The first step before a transfusion is given is to type and screen the recipient's blood.
Typing of recipient's blood determines the ABO and Rh status.
The sample is then screened for any alloantibodies that may react with donor blood.
It takes about 45 minutes to complete (depending on the method used).
The blood bank scientist also checks for special requirements of the patient (e.g. need for washed, irradiated or CMV negative blood) and the history of the patient to see if they have previously identified antibodies and any other serological anomalies.
A positive screen warrants an antibody panel/investigation to determine if it is clinically significant.
An antibody panel consists of commercially prepared group O red cell suspensions from donors that have been phenotyped for antigens that correspond to commonly encountered and clinically significant alloantibodies.
Donor cells may have homozygous (e.g. K+k+), heterozygous (K+k-) expression or no expression of various antigens (K−k−).
The phenotypes of all the donor cells being tested are shown in a chart.
The patient's serum is tested against the various donor cells.
Based on the reactions of the patient's serum against the donor cells, a pattern will emerge to confirm the presence of one or more antibodies.
Not all antibodies are clinically significant (i.e. cause transfusion reactions, HDN, etc.).
Once the patient has developed a clinically significant antibody it is vital that the patient receive antigen-negative red blood cells to prevent future transfusion reactions.
A direct antiglobulin test (Coombs test) is also performed as part of the antibody investigation.
If there is no antibody present, an immediate spin crossmatch or computer-assisted crossmatch is performed where the recipient serum and donor rbc are incubated.
In the immediate spin method, two drops of patient serum are tested against a drop of 3–5% suspension of donor cells in a test tube and spun in a serofuge.
Agglutination or hemolysis (i.e., positive Coombs test) in the test tube is a positive reaction and the unit should not be transfused.
If an antibody is suspected, potential donor units must first be screened for the corresponding antigen by phenotyping them.
Antigen negative units are then tested against the patient plasma using an antiglobulin/indirect crossmatch technique at 37 degrees Celsius to enhance reactivity and make the test easier to read.
In urgent cases where crossmatching cannot be completed, and the risk of dropping hemoglobin outweighs the risk of transfusing uncrossmatched blood, O-negative blood is used, followed by crossmatch as soon as possible.
O-negative is also used for children and women of childbearing age.
It is preferable for the laboratory to obtain a pre-transfusion sample in these cases so a type and screen can be performed to determine the actual blood group of the patient and to check for alloantibodies.
Compatibility of ABO and Rh system for Red Cell (Erythrocyte) Transfusion
This chart shows possible matches in blood transfusion between donor and receiver using ABO and Rh system.
In the same way that the safety of pharmaceutical products is overseen by pharmacovigilance, the safety of blood and blood products is overseen by haemovigilance.
This is defined by the World Health Organization (WHO) as a system "...to identify and prevent occurrence or recurrence of transfusion related unwanted events, to increase the safety, efficacy and efficiency of blood transfusion, covering all activities of the transfusion chain from donor to recipient."
The system should include monitoring, identification, reporting, investigation and analysis of adverse events near-misses and reactions related to transfusion and manufacturing.
In the UK this data is collected by an independent organisation called SHOT (Serious Hazards Of Transfusion).
Transfusions of blood products are associated with several complications, many of which can be grouped as immunological or infectious.
There is controversy on potential quality degradation during storage.
- Acute hemolytic reactions are defined according to Serious Hazards of Transfusion (SHOT) as "fever and other symptoms/signs of haemolysis within 24 hours of transfusion; confirmed by one or more of the following: a fall of Hb, rise in lactate dehydrogenase (LDH), positive direct antiglobulin test (DAT), positive crossmatch" This is due to destruction of donor red blood cells by preformed recipient antibodies. Most often this occurs because of clerical errors or improper ABO blood typing and crossmatching resulting in a mismatch in ABO blood type between the donor and the recipient. Symptoms include fever, chills, chest pain, back pain, hemorrhage, increased heart rate, shortness of breath, and rapid drop in blood pressure. When suspected, transfusion should be stopped immediately, and blood sent for tests to evaluate for presence of hemolysis. Treatment is supportive. Kidney injury may occur because of the effects of the hemolytic reaction (pigment nephropathy). The severity of the transfusion reaction is depended upon amount of donor's antigen transfused, nature of the donor's antigens, the nature and the amount of recipient antibodies.
- Delayed hemolytic reactions occur more than 24 hours after a transfusion. They usually occur within 28 days of a transfusion. They can be due to either a low level of antibodies present prior to the start of the transfusion, which are not detectable on pre-transfusion testing; or development of a new antibody against an antigen in the transfused blood. Therefore, delayed haemolytic reaction does not manifest until after 24 hours when enough amount of antibodies are available to cause a reaction. The red blood cells are removed by macrophages from the blood circulation into liver and spleen to be destroyed, which leads to extravascular haemolysis. This process usually mediated by anti-Rh and anti-Kidd antibodies. However, this type of transfusion reaction is less severe when compared to acute haemolytic transfusion reaction.
- Febrile nonhemolytic reactions are, along with allergic transfusion reactions, the most common type of blood transfusion reaction and occur because of the release of inflammatory chemical signals released by white blood cells in stored donor blood or attack on donor's white blood cells by recipient's antibodies. This type of reaction occurs in about 7% of transfusions. Fever is generally short lived and is treated with antipyretics, and transfusions may be finished as long as an acute hemolytic reaction is excluded. This is a reason for the now-widespread use of leukoreduction – the filtration of donor white cells from red cell product units.
- Allergic transfusion reactions are caused by IgE anti-allergen antibodies. When antibodies are bound to its antigens, histamine is released from mast cells and basophils. Either IgE antibodies from the donor's or recipient's side can cause the allergic reaction. It is more common in patients who have allergic conditions such as hay fever. Patient may feel itchy or having hives but the symptoms are usually mild and can be controlled by stopping the transfusion and giving antihistamines.
- Anaphylactic reactions are rare life-threatening allergic conditions caused by IgA anti-plasma protein antibodies. For patients who have selective immunoglobulin A deficiency, the reaction is presumed to be caused by IgA antibodies in the donor's plasma. The patient may present with symptoms of fever, wheezing, coughing, shortness of breath, and circulatory shock. Urgent treatment with epinephrine is needed.
- Post-transfusion purpura is an extremely rare complication that occurs after blood product transfusion and is associated with the presence of antibodies in the patient's blood directed against both the donor's and recipient's platelets HPA (human platelet antigen). Recipients who lack this protein develop sensitization to this protein from prior transfusions or previous pregnancies, can develop thrombocytopenia, bleeding into the skin, and can display purplish discolouration of skin which is known as purpura. Intravenous immunoglobulin (IVIG) is treatment of choice.
- Transfusion-related acute lung injury (TRALI) is a syndrome that is similar to acute respiratory distress syndrome (ARDS), which develops during or within 6 hours of transfusion of a plasma-containing blood product. Fever, hypotension, shortness of breath, and tachycardia often occurs in this type of reaction. For a definitive diagnosis to be made, symptoms must occur within 6 hours of transfusion, hypoxemia must be present, there must be radiographic evidence of bilateral infiltrates and there must be no evidence of left atrial hypertension (fluid overload). It occurs in 15% of the transfused patient with mortality rate of 5 to 10%. Recipient risk factors includes: end-stage liver disease, sepsis, haematological malignancies, sepsis, and ventilated patients. Antibodies to human neutrophil antigens (HNA) and human leukocyte antigens (HLA) have been associated with this type of transfusion reaction. Donor's antibodies interacting with antigen positive recipient tissue result in release of inflammatory cytokines, resulting in pulmonary capillary leakage. The treatment is supportive.
- Transfusion associated circulatory overload (TACO) is a common, yet underdiagnosed, reaction to blood product transfusion consisting of the new onset or exacerbation of three of the following within 6 hours of cessation of transfusion: acute respiratory distress, elevated brain natriuretic peptide (BNP), elevated central venous pressure (CVP), evidence of left heart failure, evidence of positive fluid balance, and/or radiographic evidence of pulmonary edema.
- Transfusion-associated graft versus host disease frequently occurs in immunodeficient patients where recipient's body failed to eliminate donor's T cells. Instead, donor's T cells attack the recipient's cells. It occurs one week after transfusion. Fever, rash, diarrhoea are often associated with this type of transfusion reaction. Mortality rate is high, with 89.7% of the patients died after 24 days. Immunosuppressive treatment is the most common way of treatment. Irradiation and leukoreduction of blood products is necessary for high risk patients for prevent T cells from attacking recipient cells.
The use of greater amount of red blood cells is associated with a high risk of infections.
In those who were given red blood only with significant anemia infection rates were 12% while in those who were given red blood at milder levels of anemia infection rates were 17%.
On rare occasions, blood products are contaminated with bacteria.
This can result in a life-threatening infection known as transfusion-transmitted bacterial infection.
The risk of severe bacterial infection is estimated, as of 2002, at about 1 in 50,000 platelet transfusions, and 1 in 500,000 red blood cell transfusions.
Blood product contamination, while rare, is still more common than actual infection.
The reason platelets are more often contaminated than other blood products is that they are stored at room temperature for short periods of time.
Contamination is also more common with longer duration of storage, especially if that means more than 5 days.
Sources of contaminants include the donor's blood, donor's skin, phlebotomist's skin, and containers.
Contaminating organisms vary greatly, and include skin flora, gut flora, and environmental organisms.
There are many strategies in place at blood donation centers and laboratories to reduce the risk of contamination.
A definite diagnosis of transfusion-transmitted bacterial infection includes the identification of a positive culture in the recipient (without an alternative diagnosis) as well as the identification of the same organism in the donor blood.
Since the advent of HIV testing of donor blood in the mid/later 1980s, ex.
Prior testing of donor blood only included testing for antibodies to HIV.
However, because of latent infection (the "window period" in which an individual is infectious, but has not had time to develop antibodies) many cases of HIV seropositive blood were missed.
The development of a nucleic acid test for the HIV-1 RNA has dramatically lowered the rate of donor blood seropositivity to about 1 in 3 million units.
As transmittance of HIV does not necessarily mean HIV infection, the latter could still occur at an even lower rate.
The transmission of hepatitis C via transfusion currently stands at a rate of about 1 in 2 million units.
As with HIV, this low rate has been attributed to the ability to screen for both antibodies as well as viral RNA nucleic acid testing in donor blood.
Other rare transmissible infections include hepatitis B, syphilis, Chagas disease, cytomegalovirus infections (in immunocompromised recipients), HTLV, and Babesia.
|+ =Occasionally present ++ =Frequently present|
|Febrile nonhemolytic||TRALI||Acute hemolytic||Bacterial contamination|
|Appearance of symptoms during or after transfusion||Usually toward end. 5-10% appear up to 2 hours after.||Early (after 10-15 ml)||Early (after 50-100 ml)||Up to 8 hours after transfusion|
|Nausea and/or vomiting||+||-||++||-|
|Hypotension / circulatory shock||-||++||++||++|
|Disseminated intravascular coagulation||-||-||++||++|
Transfusion inefficacy or insufficient efficacy of a given unit(s) of blood product, while not itself a "complication" per se, can nonetheless indirectly lead to complications – in addition to causing a transfusion to fully or partly fail to achieve its clinical purpose.
This can be especially significant for certain patient groups such as critical-care or neonatals.
For red blood cells (RBC), by far the most commonly transfused product, poor transfusion efficacy can result from units damaged by the so-called storage lesion – a range of biochemical and biomechanical changes that occur during storage.
With red cells, this can decrease viability and ability for tissue oxygenation.
Although some of the biochemical changes are reversible after the blood is transfused, the biomechanical changes are less so, and rejuvenation products are not yet able to adequately reverse this phenomenon.
There has been controversy about whether a given product unit's age is a factor in transfusion efficacy, specifically about whether "older" blood directly or indirectly increases risks of complications.
Studies have not been consistent on answering this question, with some showing that older blood is indeed less effective but with others showing no such difference; these developments are being closely followed by hospital blood bankers – who are the physicians, typically pathologists, who collect and manage inventories of transfusable blood units.
Certain regulatory measures are in place to minimize RBC storage lesion – including a maximum shelf life (currently 42 days), a maximum auto-hemolysis threshold (currently 1% in the US, 0.8% in Europe), and a minimum level of post-transfusion RBC survival in vivo (currently 75% after 24 hours).
However, all of these criteria are applied in a universal manner that does not account for differences among units of product.
For example, testing for the post-transfusion RBC survival in vivo is done on a sample of healthy volunteers, and then compliance is presumed for all RBC units based on universal (GMP) processing standards (of course, RBC survival by itself does not guarantee efficacy, but it is a necessary prerequisite for cell function, and hence serves as a regulatory proxy).
Opinions vary as to the "best" way to determine transfusion efficacy in a patient in vivo.
In general, there are not yet any in vitro tests to assess quality or predict efficacy for specific units of RBC blood product prior to their transfusion, though there is exploration of potentially relevant tests based on RBC membrane properties such as erythrocyte deformability and erythrocyte fragility (mechanical).
Physicians have adopted a so-called "restrictive protocol" – whereby transfusion is held to a minimum – in part because of the noted uncertainties surrounding storage lesion, in addition to the very high direct and indirect costs of transfusions.
Of course, restrictive protocol is not an option with some especially vulnerable patients who may require the best possible efforts to rapidly restore tissue oxygenation.
Although transfusions of platelets are far less numerous (relative to RBC), platelet storage lesion and resulting efficacy loss is also a concern.
Working at the Royal Society in the 1660s, the physician Richard Lower began examining the effects of changes in blood volume on circulatory function and developed methods for cross-circulatory study in animals, obviating clotting by closed arteriovenous connections.
The new instruments he was able to devise enabled him to perform the first reliably documented successful transfusion of blood in front of his distinguished colleagues from the Royal Society.
According to Lower's account, "...towards the end of February 1665 [I] selected one dog of medium size, opened its jugular vein, and drew off blood, until its strength was nearly gone.
Then, to make up for the great loss of this dog by the blood of a second, I introduced blood from the cervical artery of a fairly large mastiff, which had been fastened alongside the first, until this latter animal showed … it was overfilled … by the inflowing blood."
After he "sewed up the jugular veins", the animal recovered "with no sign of discomfort or of displeasure".
Lower had performed the first blood transfusion between animals.
He was then "requested by the Honorable [Robert] Boyle … to acquaint the Royal Society with the procedure for the whole experiment", which he did in December 1665 in the Society's Philosophical Transactions.
The first blood transfusion from animal to human was administered by Dr. Jean-Baptiste Denys, eminent physician to King Louis XIV of France, on June 15, 1667.
He transfused the blood of a sheep into a 15-year-old boy, who survived the transfusion.
Denys performed another transfusion into a labourer, who also survived.
Both instances were likely due to the small amount of blood that was actually transfused into these people.
This allowed them to withstand the allergic reaction.
Denys's third patient to undergo a blood transfusion was Swedish Baron Gustaf Bonde.
He received two transfusions.
After the second transfusion Bonde died.
In the winter of 1667, Denys performed several transfusions on Antoine Mauroy with calf's blood.
On the third account Mauroy died.
Six months later in London, Lower performed the first human transfusion of animal blood in Britain, where he "superintended the introduction in [a patient's] arm at various times of some ounces of sheep's blood at a meeting of the Royal Society, and without any inconvenience to him."
The recipient was Arthur Coga, "the subject of a harmless form of insanity."
Sheep's blood was used because of speculation about the value of blood exchange between species; it had been suggested that blood from a gentle lamb might quiet the tempestuous spirit of an agitated person and that the shy might be made outgoing by blood from more sociable creatures.
Coga received 20 shillings (equivalent to £173 in 2019) to participate in the experiment.
Shortly after, Lower moved to London, where his growing practice soon led him to abandon research.
These early experiments with animal blood provoked a heated controversy in Britain and France.
Finally, in 1668, the Royal Society and the French government both banned the procedure.
The Vatican condemned these experiments in 1670.
Blood transfusions fell into obscurity for the next 150 years.
The science of blood transfusion dates to the first decade of the 20th century, with the discovery of distinct blood types leading to the practice of mixing some blood from the donor and the receiver before the transfusion (an early form of cross-matching).
In 1818 following experiments with animals, he performed the first successful transfusion of human blood to treat postpartum hemorrhage.
Blundell used the patient's husband as a donor, and extracted four ounces of blood from his arm to transfuse into his wife.
During the years 1825 and 1830, Blundell performed 10 transfusions, five of which were beneficial, and published his results.
He also invented a number of instruments for the transfusion of blood.
He made a substantial amount of money from this endeavour, roughly $2 million ($50 million real dollars).
However, early transfusions were risky and many resulted in the death of the patient.
By the late 19th century, blood transfusion was regarded as a risky and dubious procedure, and was largely shunned by the medical establishment.
Work to emulate James Blundell continued in Edinburgh.
In 1845 the Edinburgh Journal described the successful transfusion of blood to a woman with severe uterine bleeding.
The largest series of early successful transfusions took place at the Edinburgh Royal Infirmary between 1885 and 1892.
Edinburgh later became the home of the first blood donation and blood transfusion services.
Landsteiner discovered that adverse effects arise from mixing blood from two incompatible individuals.
He found that mixing incompatible types triggers an immune response and the red blood-cells clump.
The immunological reaction occurs when the receiver of a blood transfusion has antibodies against the donor blood-cells.
Landsteiner's work made it possible to determine blood group and allowed blood transfusions to take place much more safely.
For his discovery he won the Nobel Prize in Physiology and Medicine in 1930; many other blood groups have been discovered since.
George Washington Crile is credited with performing the first surgery using a direct blood transfusion in 1906 at St. Alexis Hospital in Cleveland while a professor of surgery at Case Western Reserve University.
Jan Janský also discovered the human blood groups; in 1907 he classified blood into four groups: I, II, III, IV.
His nomenclature is still used in Russia and in states of the former USSR, in which blood types O, A, B, and AB are respectively designated I, II, III, and IV.
Dr. William Lorenzo Moss's (1876–1957) Moss-blood typing technique of 1910 was widely used until World War II.
William Stewart Halsted, M.D. (September 23, 1852 – September 7, 1922), an American surgeon, performed one of the first blood transfusions in the United States.
He had been called to see his sister after she had given birth.
He found her moribund from blood loss, and in a bold move withdrew his own blood, transfused his blood into his sister, and then operated on her to save her life.
Blood banks in WWI
Main article: Blood bank
While the first transfusions had to be made directly from donor to receiver before coagulation, it was discovered that by adding anticoagulant and refrigerating the blood it was possible to store it for some days, thus opening the way for the development of blood banks.
His attempts, using phosphate of soda, however, proved unsuccessful.
Both used sodium citrate as an anticoagulant.
The First World War (1914-1918) acted as a catalyst for the rapid development of blood banks and transfusion techniques.
Canadian doctor and Lieutenant Lawrence Bruce Robertson became instrumental in persuading the Royal Army Medical Corps to adopt the use of blood transfusion at the Casualty Clearing Stations for the wounded.
In October 1915 Robertson performed his first wartime transfusion with a syringe to a patient suffering from multiple shrapnel wounds.
Robertson published his findings in the British Medical Journal in 1916 and, with the help of a few like-minded individuals (including the eminent physician Edward William Archibald (1872-1945), who introduced the citrate anticoagulant method), was able to persuade the British authorities of the merits of blood transfusion.
Oswald Hope Robertson, a medical researcher and U.S. officer, was attached to the ArmyRAMC in 1917, where he became instrumental in establishing the first blood banks in preparation for the anticipated Third Battle of Ypres.
Robertson also experimented with preserving separated red blood cells in iced bottles.
Geoffrey Keynes, a British surgeon, developed a portable machine that could store blood to enable transfusions to be carried out more easily.
The secretary of the British Red Cross, Percy Oliver, established the world's first blood-donor service in 1921.
In that year, Oliver was contacted by King's College Hospital, where they were in urgent need of a blood donor.
After providing a donor, Oliver set about organizing a system for the voluntary registration of blood donors at clinics around London, with Sir Geoffrey Keynes appointed as a medical adviser.
Volunteers were subjected to a series of physical tests to establish their blood group.
The London Blood Transfusion Service was free of charge and expanded rapidly in its first few years of operation.
By 1925 it was providing services for almost 500 patients; it was incorporated into the structure of the British Red Cross in 1926.
France, Germany, Austria, Belgium, Australia and Japan established similar services.
Bogdanov was motivated, at least in part, by a search for eternal youth, and remarked with satisfaction on the improvement of his eyesight, suspension of balding, and other positive symptoms after receiving 11 transfusions of whole blood.
Yudin performed such a transfusion successfully for the first time on March 23, 1930 and reported his first seven clinical transfusions with cadaveric blood at the Fourth Congress of Ukrainian Surgeons at Kharkiv in September.
However, this method was never used widely, even in the Soviet Union.
Duran joined the Transfusion Service at the Barcelona Hospital at the start of the conflict, but the hospital was soon overwhelmed by the demand for blood and the paucity of available donors.
With support from the Department of Health of the Spanish Republican Army, Duran established a blood bank for the use of wounded soldiers and civilians.
The 300–400 mL of extracted blood was mixed with 10% citrate solution in a modified Duran Erlenmeyer flask.
The blood was stored in a sterile glass enclosed under pressure at 2 °C.
During 30 months of work, the Transfusion Service of Barcelona registered almost 30,000 donors, and processed 9,000 liters of blood.
In setting up a hospital laboratory that preserved, refrigerated and stored donor blood, Fantus originated the term "blood bank".
Within a few years, hospital and community blood-banks were established across the United States.
With the outbreak of war appearing imminent in 1938, the War Office created the Army Blood Supply Depot (ABSD) in Bristol, headed by Lionel Whitby and in control of four large blood-depots around the country.
British policy through the war was to supply military personnel with blood from centralized depots, in contrast to the approach taken by the Americans and Germans where troops at the front were bled to provide required blood.
The British method proved more successful in adequately meeting all requirements, and over 700,000 donors were bled over the course of the war.
This system evolved into the National Blood Transfusion Service established in 1946, the first national service to be implemented.
Stories tell of Nazis in Eastern Europe during World War II using captive children as repeated involuntary blood-donors.
At the onset of World War II, liquid plasma was used in Britain.
A dried plasma package was developed, which reduced breakage and made transportation, packaging, and storage much simpler.
The resulting dried plasma package came in two tin cans containing 400 mL bottles.
One bottle contained enough distilled water to reconstitute the dried plasma contained within the other bottle.
In about three minutes, the plasma would be ready to use and could stay fresh for around four hours.
Another important breakthrough came in 1937–40 when Karl Landsteiner (1868-1943), Alex Wiener, Philip Levine, and R.E.
Three years later, the introduction by J.F. and Patrick L. Mollison of Loutitacid–citrate–dextrose (ACD) solution, which reduced the volume of anticoagulant, permitted transfusions of greater volumes of blood and allowed longer-term storage.
Carl Walter and W.P.
Murphy Jr. introduced the plastic bag for blood collection in 1950.
Replacing breakable glass bottles with durable plastic bags made from PVC allowed for the evolution of a collection system capable of safe and easy preparation of multiple blood components from a single unit of whole blood.
In the field of cancer surgery, the replacement of massive blood-loss became a major problem.
The cardiac-arrest rate was high.
In 1963 C. Paul Boyan and William S. Howland discovered that the temperature of the blood and the rate of infusion greatly affected survival rates, and introduced blood warming to surgery.
Further extending the shelf-life of stored blood up to 42 days was an anticoagulant preservative, CPDA-1, introduced in 1979, which increased the blood supply and facilitated resource-sharing among blood banks.
As of 2006 about 15 million units of blood products were transfused per year in the United States.
By 2013 the number had declined to about 11 million units, because of the shift towards laparoscopic surgery and other surgical advances and studies that have shown that many transfusions were unnecessary.
For example, the standard of care reduced the amount of blood transfused in one case from 750 to 200 ml.
To ensure the safety of blood transfusion to pediatric patients, hospitals are taking additional precautions to avoid infection and prefer to use specially tested pediatric blood units that are guaranteed negative for Cytomegalovirus.
Most guidelines recommend the provision of CMV-negative blood components and not simply leukoreduced components for newborns or low birthweight infants in whom the immune system is not fully developed.
These specific requirements place additional restrictions on blood donors who can donate for neonatal use.
vnv Neonatal transfusions typically fall into one of two categories:
- "Top-up" transfusions, to replace losses due to investigational losses and correction of anemia.
- Exchange (or partial exchange) transfusions are done for removal of bilirubin, removal of antibodies and replacement of red cells (e.g., for anemia secondary to thalassemias and other hemoglobinopathies).
Significant blood loss
A massive transfusion protocol is used when significant blood loss is present such as in major trauma, when more than ten units of blood are needed.
Packed red blood cells, fresh frozen plasma, and platelets are generally administered.
Unknown blood type
Because blood type O negative is compatible with anyone, it is often overused and in short supply.
According to the American Association of Blood Banks, the use of this blood should be restricted to persons with O negative blood, as nothing else is compatible with them, and women who might be pregnant and for whom it would be impossible to do blood group testing before giving them emergency treatment.
Whenever possible, the AABB recommends that O negative blood be conserved by using blood type testing to identify a less scarce alternative.
Research into alternatives
See also: Blood substitutes
Although there are clinical situations where transfusion with red blood cells is the only clinically appropriate option, clinicians look at whether alternatives are feasible.
This can be due to several reasons, such as patient safety, economic burden or scarcity of blood.
Guidelines recommend blood transfusions should be reserved for patients with or at risk of cardiovascular instability due to the degree of their anaemia.
In these cases parenteral iron is recommended.
Thus far, there are no available oxygen-carrying blood substitutes, which is the typical objective of a blood (RBC) transfusion; however, there are widely available non-blood volume expanders for cases where only volume restoration is required.
These are helping doctors and surgeons avoid the risks of disease transmission and immune suppression, address the chronic blood donor shortage, and address the concerns of Jehovah's Witnesses and others who have religious objections to receiving transfused blood.
A number of blood substitutes have been explored (and still are), but thus far they all suffer from many challenges.
Most attempts to find a suitable alternative to blood thus far have concentrated on cell-free hemoglobin solutions.
If successful, such a blood substitute could save many lives, particularly in trauma where massive blood loss results.
Minor blood transfusions are used by a minority of nyaope drug addicts in South Africa to economically share the high the drug induces in a practice colloquially known as Bluetoothing, named after the wireless technology of the same name.
Main article: Blood type (non-human)
Veterinarians also administer transfusions to other animals.
Various species require different levels of testing to ensure a compatible match.
However, in many species (especially horses and dogs), cross matching is not required before the first transfusion, as antibodies against non-self cell surface antigens are not expressed constitutively – i.e. the animal has to be sensitized before it will mount an immune response against the transfused blood.
The rare and experimental practice of inter-species blood transfusions is a form of xenograft.
Credits to the contents of this page go to the authors of the corresponding Wikipedia page: en.wikipedia.org/wiki/Blood transfusion.